Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Dr. Reddy’s Laboratories Limited. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Dr. Reddy’s Laboratories Limited (RDY) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s Laboratories” or “the Company”) (NYSE: RDY). Investors who purchased Dr. Reddy’s Laboratories securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Dr. Reddy’s Laboratories has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On July 22, 2026, Dr. Reddy’s Laboratories reported first-quarter fiscal 2027 financial results that missed expectations and disclosed a ₹2.4 billion provision related to out-of-specification semaglutide batches. During the accompanying earnings call, Chief Executive Officer Erez Israeli stated that there was “no impact on the product’s existing global regulatory filings” and “no patient-safety impact associated with product already supplied to the market.” This disclosure followed the Company’s earlier statements highlighting semaglutide approvals and product launches, including Obeda in Canada and the approval of oral semaglutide in India. Following this news, Dr. Reddy’s Laboratories’ stock price fell approximately 9%.
What Should Dr. Reddy’s Laboratories Limited (RDY) Investors Do?
If you are aware of any facts relating to this investigation or purchased Dr. Reddy’s Laboratories securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Is Dr. Reddy’s Laboratories Limited (NYSE: RDY) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”